

## Anabella Mayorga

---

**From:** Sandra Darling <sandradarling47@gmail.com>  
**Sent:** Monday, March 10, 2025 7:01 PM  
**To:** House Judiciary Committee; june.speakman@gmail.com  
**Subject:** HB 5913

**Follow Up Flag:** Follow up  
**Flag Status:** Completed

Chairman Craven and members of the House Judiciary Committee:

I am writing to you today in **SUPPORT** of House Bill 5913.

House Bill 5913 would address an anticompetitive practice sometimes referred to as a “pay-for-delay” agreement. A pay-for-delay agreement is an arrangement between a brand name drug manufacturer and a competing generic drug manufacturer in which the generic drug manufacturer agrees to delay entry into the market of its generic drug in exchange for something of value from the brand name drug manufacturer, such as money or a promise of limited legal action.

“Pay-for-delay” practices delay the entry of generic drugs to the market, increase costs, and ultimately force consumers to pay more for medications that are prescribed by their doctors for certain medical conditions which may not respond to other drugs on the market.

Now patients must choose the drug they need, which is more expensive than a generic drug, or remain untreated if their budget is too limited.

I urge your support on the passage of HB # 5913 so more Rhode Islanders can obtain the medications they need sooner at a reasonable cost as a generic.

*Sandra Darling, AARP Advocacy Volunteer and Retired RN  
7 Fort Hill Rd  
Bristol, RI 02809  
904-860-1566 cell/text*

•

*Sandra*